Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and therapy-resistant prostate cancer. Based on research at the University of Queensland’s School of Pharmacy and Pharmaceutical Sciences, QED-203 is being developed by the Queensland Emory Drug Discovery Initiative.